| B02BD02 |
Coagulation factor VIII (Octocog alfa) |
Recombinate 1000 IU |
Powder and solvent for solution for injection |
1000 |
IU |
1 |
Baxter AG, Австрия |
500 |
U |
1278.13 |
639.065 |
1278.13 |
100% |
|
Съгласно РУ |
№ 190/ 22.08.2011; КЦРР-259/06.03.2012; КЦРР-1549/01.11.2012 |
04.01.2013 |
08.09.2012 |
Заличен |
1147 |
| B02BD02 |
Coagulation factor VIII (Octocog alfa) |
Recombinate 250 IU |
Powder and solvent for solution for injection |
250 |
IU |
1 |
Baxter AG, Австрия |
500 |
U |
328.36 |
645.08002 |
322.54 |
100% |
|
Съгласно РУ |
№ 190/ 22.08.2011; КЦРР-259/06.03.2012; КЦРР-2102/25.01.2013. |
20.02.2013 |
08.09.2012 |
Заличен |
1145 |
| B02BD02 |
Coagulation factor VIII (Octocog alfa) |
Recombinate 500 IU |
Powder and solvent for solution for injection |
500 |
IU |
1 |
Baxter AG, Австрия |
500 |
U |
645.08 |
645.08002 |
645.08 |
100% |
|
Съгласно РУ |
№ 190/ 22.08.2011; КЦРР-259/06.03.2012; КЦРР-2102/25.01.2013. |
20.02.2013 |
08.09.2012 |
Заличен |
1146 |
| B02BD02 |
Coagulation factor VIII (Moroctocog alfa) |
ReFacto AF |
Powder and solvent for solution for injection |
500 |
IU |
1 pre filled syringe + 1 plunger rod + 1 sterile infusion set + 2 alcohol swabs + 1 plaster + 1 gauze + 1 vented sterile cap |
Pfizer Europe MA EEIG, Белгия |
500 |
IU |
613.54 |
613.54 |
613.54 |
100% |
|
Съгласно РУ |
НСР-5767/09.03.2015.; НСР-7531/19.11.2015.; НСР-17477/13.12.2018 |
02.01.2019 |
|
Активен |
3640 |
| B02BD02 |
Coagulation factor VIII (Moroctocog alfa) |
ReFacto AF |
Powder and solvent for solution for injection |
500 |
IU |
1 |
Pfizer Europe MA EEIG, Белгия |
500 |
IU |
619.68 |
613.54 |
613.54 |
100% |
|
Съгласно РУ |
№ 180/ 27.07.2011.; КЦРР-1462/02.10.2012; НСР-2501/24.01.2014.; НСР-7012/25.08.2015.; НСР-11065/01.12.2016 г.; НСР-17756/17.01.2019; НСР-18103/07.03.2019; НСР-20965/05.03.2020; НСР-21098/30.03.2020 Предварително изпълнение |
02.07.2020 |
08.09.2012 |
Заличен |
2453 |
| B02BD02 |
Coagulation factor VIII (Moroctocog alfa) |
ReFacto AF |
Powder and solvent for solution for injection |
500 |
IU |
1 |
Pfizer Europe MA EEIG, Белгия |
500 |
IU |
619.68 |
613.54 |
613.54 |
100% |
|
Съгласно РУ |
№ 180/ 27.07.2011.; КЦРР-1462/02.10.2012; НСР-2501/24.01.2014.; НСР-7012/25.08.2015.; НСР-11065/01.12.2016 г.; НСР-17756/17.01.2019; НСР-18103/07.03.2019; НСР-20965/05.03.2020; НСР-21098/30.03.2020 Предварително изпълнение |
02.04.2020 |
08.09.2012 |
Заличен |
2453 |
| B02BD02 |
Coagulation factor VIII (Moroctocog alfa) |
ReFacto AF |
Powder and solvent for solution for injection |
1000 |
IU |
1 |
Pfizer Limited, Обединено Кралство |
500 |
U |
1340.68 |
670.34003 |
1340.68 |
100% |
|
Съгласно РУ |
№ 180/ 27.07.2011.; КЦРР-1462/02.10.2012.; КЦРР-2039/21.01.2013; КЦРР-2536/14.03.2013. |
04.04.2013 |
08.09.2012 |
Заличен |
1648 |
| B02BD02 |
Coagulation factor VIII (Moroctocog alfa) |
ReFacto AF |
Powder and solvent for solution for injection |
250 |
IU |
1 |
Pfizer Limited, Обединено Кралство |
500 |
U |
348.11 |
674.82501 |
337.41 |
100% |
|
Съгласно РУ |
№ 180/ 27.07.2011.; КЦРР-1462/02.10.2012; НСР-3155/26.03.2014 |
16.04.2014 |
08.09.2012 |
Заличен |
1013 |
| B02BD02 |
Coagulation factor VIII |
B02BD02 Coagulation factor VIII (efmoroctocog alfa, rurioctocog alfa pegol,damoctocog alfa pegol) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| B02BD02 |
Coagulation factor VIII (rurioctocog alfa pegol) |
Adynovi |
Powder and solvent for injection |
1000 |
IU |
1 vial + 1 vial (solvent 2 ml), preassembled whit reconstitution device |
Baxalta Innovations GmbH, Австрия |
500 |
IU |
1943.16 |
736.87167 |
1473.74 |
100% |
|
Съгласно РУ |
НСР-17647/21.12.2018 предварително изпълнение |
02.08.2019 |
|
Активен |
16388 |
| B02BD02 |
Coagulation factor VIII (rurioctocog alfa pegol) |
Adynovi |
Powder and solvent for injection |
500 |
IU |
1 vial + 1 vial (solvent 2 ml), preassembled whit reconstitution device |
Baxalta Innovations GmbH, Австрия |
500 |
IU |
977.58 |
736.87167 |
736.87 |
100% |
|
Съгласно РУ |
НСР-17647/21.12.2018 предварително изпълнение |
02.08.2019 |
|
Активен |
16387 |
| B02BD02 |
coagulation factor VIII (efmoroctocog alfa) |
Elocta |
Powder and solvent for solution for injection |
250 |
IU |
1 vial (powder)+1 pre-filled syringe (solvent) |
Swedish Orphan Biovitrum AB, Швеция |
500 |
IU |
379.44 |
736.87167 |
368.44 |
100% |
|
Съгласно РУ |
НСР-12362/18.04.2017; НСР-15072/23.02.2018; КП-56/19.06.2019 и НСР-17249/14.11.2018 |
02.08.2019 |
|
Активен |
15666 |
| B02BD02 |
coagulation factor VIII (efmoroctocog alfa) |
Elocta |
Powder and solvent for solution for injection |
1000 |
IU |
1 vial (powder)+1 pre-filled syringe (solvent) |
Swedish Orphan Biovitrum AB, Швеция |
500 |
IU |
1481.74 |
736.87167 |
1473.74 |
100% |
|
Съгласно РУ |
НСР-12362/18.04.2017; НСР-15073/23.02.2018; КП-54/19.06.2019 и НСР-17247/14.11.2018 |
02.08.2019 |
|
Активен |
15668 |
| B02BD02 |
coagulation factor VIII (efmoroctocog alfa) |
Elocta |
Powder and solvent for solution for injection |
500 |
IU |
1 vial (powder)+ 1 pre-filled syringe (solvent) |
Swedish Orphan Biovitrum AB, Швеция |
500 |
IU |
746.87 |
736.87167 |
736.87 |
100% |
|
Съгласно РУ |
НСР-12362/18.04.2017; НСР-13653/01.09.2017; КП-55/19.06.2019 и НСР-17248/14.11.2018 |
02.08.2019 |
|
Активен |
15667 |
| B02BD02 |
coagulation factor VIII (efmoroctocog alfa) |
Elocta |
Powder and solvent for solution for injection |
1500 |
IU |
1 vial (powder) +1 pre-filled syringe (solvent) |
Swedish Orphan Biovitrum AB, Швеция |
500 |
IU |
2216.6 |
736.87167 |
2210.62 |
100% |
|
Съгласно РУ |
НСР-15271/16.03.2018 Предварително изпълнение; КП-53/19.06.2019 и НСР-17246/14.11.2018 |
02.08.2019 |
|
Активен |
16049 |
| B02BD02 |
coagulation factor VIII (efmoroctocog alfa) |
Elocta |
Powder and solvent for solution for injection |
2000 |
IU |
1 vial (powder) +1 pre-filled syringe (solvent) |
Swedish Orphan Biovitrum AB, Швеция |
500 |
IU |
2951.47 |
736.87167 |
2947.49 |
100% |
|
Съгласно РУ |
НСР-15271/16.03.2018 Предварително изпълнение; КП-52/19.06.2019 и НСР-17245/14.11.2018 |
02.08.2019 |
|
Активен |
16050 |
| B02BD02 |
coagulation factor VIII (efmoroctocog alfa) |
Elocta |
Powder and solvent for solution for injection |
3000 |
IU |
1 vial (powder) +1 pre-filled syringe (solvent) |
Swedish Orphan Biovitrum AB, Швеция |
500 |
IU |
4421.23 |
736.87167 |
4421.23 |
100% |
|
Съгласно РУ |
НСР-15271/16.03.2018 Предварително изпълнение |
02.08.2019 |
|
Активен |
16051 |
| B02BD02 |
Coagulation factor VIII (Damoctocog alfa pegol) |
Jivi |
Powder and solvent for solution for injection |
500 |
IU |
1 vial with powder + 1 pre-filled syringe with 2.5 ml solvent + 1 syringe plunger rod + 1 vial adapter + 1 venipuncture set |
Bayer AG, Германия |
500 |
IU |
927.32 |
736.87167 |
736.87 |
100% |
|
Съгласно РУ |
НСР-19863/27.09.2019 |
02.11.2019 |
|
Активен |
16728 |
| B02BD02 |
Coagulation factor VIII (Damoctocog alfa pegol) |
Jivi |
Powder and solvent for solution for injection |
1000 |
IU |
1 vial with powder + 1 pre-filled syringe with 2.5 ml solvent + 1 syringe plunger rod + 1 vial adapter + 1 venipuncture set |
Bayer AG, Германия |
500 |
IU |
1842.66 |
736.87167 |
1473.74 |
100% |
|
Съгласно РУ |
НСР-19863/27.09.2019 |
02.11.2019 |
|
Активен |
16729 |
| B02BD03 |
coagulation factor, Factor VIII inhibitor bypassing activity |
B02BD03 coagulation factor, Factor VIII inhibitor bypassing activity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| B02BD03 |
factor VIII inhibitor bypassyng activity |
Feiba |
Powder and solvent for solution for infusion |
25 U/ml (500 U) |
|
1 vial 500 U powder for solution for infusion+1 vial 20 ml water for injection+1 administration set |
Baxalta Innovations GmbH, Австрия |
10000 |
IU |
752.57 |
15051.4 |
752.57 |
100% |
|
Съгласно РУ |
НСР-13563/25.08.2017; НСР-15794/04.06.2018 (предварително изпълнение); НСР-19667/29.08.2019 |
02.10.2019 |
|
Активен |
15828 |
| B02BD03 |
factor VIII inhibitor bypassyng activity |
Feiba NF |
Powder and solvent for solution for injection |
500 U |
|
1 pre-filled syringe + powd.vial + solv.vial 20 ml + adm.set |
Baxter AG, Австрия |
10000 |
IU |
762.31 |
15246.2 |
762.31 |
100% |
|
Съгласно РУ |
№ 190/ 22.08.2011; НСР-2195/20.12.2013; НСР-14088/06.10.2017; НСР-15691/17.05.2018; НСР-18079/01.03.2019 |
02.04.2019 |
08.09.2012 |
Заличен |
2439 |
| B02BD04 |
Coagulation factor IX |
B02BD04 Coagulation factor IX |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| B02BD04 |
Coagulation factor IX |
Aimafix |
Powder and solvent for solution for infusion |
500 |
IU |
1 |
Kedrion S.p.A., Италия |
1 |
IU |
421.18 |
0.8114 |
405.7 |
100% |
|
Съгласно РУ |
№ 164/ 20.04.2011; НСР-13031/23.06.2017 предварително изпълнение,КП-34/29.05.2017 и НСР-12077/21.03.2017,Протокол № 230/22.06.2017; НСР-13258/18.07.2017 предварително изпълнение; НСР-17764/17.01.2019; НСР-17765/17.01.2019 |
02.02.2019 |
08.09.2012 |
Активен |
369 |
| B02BD04 |
Coagulation factor IX |
IMMUNINE |
Powder and solvent for solution for injection/infusion |
600 |
IU |
1 |
Baxalta Innovations GmbH, Австрия |
1 |
IU |
486.84 |
0.8114 |
486.84 |
100% |
|
Съгласно РУ |
№ 190/ 22.08.2011; НСР-2198/20.12.2013; НСР-3381/29.04.2014; Протокол № 230/22.06.2017 |
02.02.2019 |
08.09.2012 |
Активен |
2442 |